Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | RAD51C A279P |
| Gene Variant Detail | |
| Relevant Treatment Approaches | Olaparib |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| RAD51C A279P | Advanced Solid Tumor | sensitive | Olaparib | Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, the expression of RAD51C A279P sensitized RAD51C-deficient cells to Lynparza (olaparib) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112). | 37253112 |
| RAD51C A279P | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, the expression of RAD51C A279P sensitized RAD51C-deficient cells to Platinol (cisplatin) treatment in culture, resulting in decreased cell proliferation (PMID: 37253112). | 37253112 | |
| RAD51C A279P | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) decreased viability in cells expressing RAD51C A279P in culture (PMID: 40670332). | 40670332 | |
| RAD51C A279P | Advanced Solid Tumor | sensitive | Olaparib | Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, Lynparza (olaparib) decreased viability in cells expressing RAD51C A279P in culture (PMID: 40670332). | 40670332 |